Kathleen Brady of the PDPH presented the annual report on the HIV epidemic in Philadelphia at the February 2017 meeting of the Philadelphia Ryan White Part A Planning Council.
Philadelphia FIGHT's PrEP Retention and Adherence Coordinator Devon Clark presented on HIV Pre-exposure Prophylaxis (PrEP) at the September 2016 meeting of the Positive Committee.
In Zimbabwe, only 57% of adult women and 34% of adult men have been tested for HIV and received their results. To address this testing gap, HIV self-testing is being introduced to complement current HIV testing strategies and help Zimbabwe achieve its goal of having 90% of people living with HIV know their status. A pilot study is underway to evaluate the acceptability, feasibility, accuracy, and ability to link people to care, treatment or prevention services of HIV self-testing using the OraQuick Advance oral test. Results are expected in June and will inform the larger UNITAID HIV STAR project starting that month aimed at further increasing HIV testing rates in Zimbabwe.
This document discusses HIV pre-exposure prophylaxis (PrEP). It summarizes evidence from clinical trials that taking the antiretroviral medication Truvada daily reduces the risk of HIV infection by 86%. It acknowledges concerns that PrEP could reduce condom use or encourage risky behavior, but clinical trials found high adherence to daily dosing was very protective. Immediate cost is a major barrier to widespread use, but PrEP may become more affordable over time, similar to oral contraceptives. Guidelines are needed on targeting high-risk groups and determining how long individuals need to remain on PrEP.
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"StopTb Italia
This document discusses the challenges of diagnosing HIV, AIDS, and co-infections. It notes that distinguishing between HIV infection, AIDS, and co-infections can be difficult. Point-of-care rapid tests have helped increase HIV testing, though they cannot identify acute HIV infections. The document emphasizes the importance of confirming positive rapid HIV tests with supplemental tests due to the potential for false positives in low prevalence populations.
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
At the end of the training, participants will be able to:
State the indications for PrEP
State the eligibility for PrEP
Name the 5 main eligibility criteria for PrEP
Explain how to exclude Acute HIV Infection
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
Philadelphia FIGHT's PrEP Retention and Adherence Coordinator Devon Clark presented on HIV Pre-exposure Prophylaxis (PrEP) at the September 2016 meeting of the Positive Committee.
In Zimbabwe, only 57% of adult women and 34% of adult men have been tested for HIV and received their results. To address this testing gap, HIV self-testing is being introduced to complement current HIV testing strategies and help Zimbabwe achieve its goal of having 90% of people living with HIV know their status. A pilot study is underway to evaluate the acceptability, feasibility, accuracy, and ability to link people to care, treatment or prevention services of HIV self-testing using the OraQuick Advance oral test. Results are expected in June and will inform the larger UNITAID HIV STAR project starting that month aimed at further increasing HIV testing rates in Zimbabwe.
This document discusses HIV pre-exposure prophylaxis (PrEP). It summarizes evidence from clinical trials that taking the antiretroviral medication Truvada daily reduces the risk of HIV infection by 86%. It acknowledges concerns that PrEP could reduce condom use or encourage risky behavior, but clinical trials found high adherence to daily dosing was very protective. Immediate cost is a major barrier to widespread use, but PrEP may become more affordable over time, similar to oral contraceptives. Guidelines are needed on targeting high-risk groups and determining how long individuals need to remain on PrEP.
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"StopTb Italia
This document discusses the challenges of diagnosing HIV, AIDS, and co-infections. It notes that distinguishing between HIV infection, AIDS, and co-infections can be difficult. Point-of-care rapid tests have helped increase HIV testing, though they cannot identify acute HIV infections. The document emphasizes the importance of confirming positive rapid HIV tests with supplemental tests due to the potential for false positives in low prevalence populations.
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
At the end of the training, participants will be able to:
State the indications for PrEP
State the eligibility for PrEP
Name the 5 main eligibility criteria for PrEP
Explain how to exclude Acute HIV Infection
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
The document discusses using HIV program data to evaluate gaps and disparities in linkage to care. It provides examples of how Louisiana measures linkage, retention, and viral suppression, and presents continuum of care data for the state overall and by region, race/ethnicity, and testing site. Linkage to care rates for newly diagnosed individuals are shown to be improving over time but still vary between regions and community-based organizations. The document encourages evaluating one's own agency's linkage data and identifying opportunities for the State HIV Program to provide more useful data support.
The Kenya HIV Testing Services Guidelines 2015Cheryl Johnson
The document provides guidelines for HIV Testing Services in Kenya. It outlines the background of HIV testing in Kenya since the first diagnosis over 30 years ago. It notes that testing approaches have evolved from expensive laboratory tests requiring complex procedures to more simplified point-of-care testing kits, resulting in more Kenyans knowing their status. The guidelines aim to ensure quality services are provided to all clients accessing health facilities for HIV services. It emphasizes updated guidance on HIV Testing Services in line with current knowledge and the country's 90-90-90 strategy to identify people living with HIV so they can access treatment.
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Hivlife Info
In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
This document provides information on PrEP (pre-exposure prophylaxis) for HIV. It discusses current US recommendations for PrEP, including identifying high-risk candidates such as men who have sex with men, transgender individuals, injection drug users, and heterosexual men and women. The document reviews PrEP clinical trials that found risk of HIV transmission was lowest with consistent PrEP use. It outlines guidelines for providing PrEP, including testing, prescribing Truvada, monitoring side effects, and supporting adherence. Discontinuing PrEP guidelines are also reviewed.
Jill Blumenthal, MD
Assistant Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
This document provides information on HIV/AIDS including its epidemiology, transmission, stages, diagnosis, treatment and prevention. It describes HIV/AIDS as a global public health issue and outlines prevention strategies like safe sex practices, antiretroviral treatment, prevention of mother-to-child transmission and harm reduction for intravenous drug users. Statistics on HIV prevalence in Pakistan are presented alongside the national AIDS control program and its strategies to promote awareness, testing and care.
HIV self-testing and linkage in Africa. The document summarizes a presentation on HIV self-testing research in Africa. It discusses (1) the need for HIV self-testing in Africa due to low testing rates and knowledge of HIV status, (2) completed and ongoing studies of HIV self-testing in various African countries, and (3) priorities for future research including improving accuracy, evaluating new models for linkage to care, and assessing implementation in different populations and settings.
What is epidemic control after 2020 mwango 04082021Albert Mwango
This document discusses epidemic control in the context of HIV/AIDS. It defines epidemic control as reaching a point where new HIV infections fall below deaths from all causes in infected individuals. It outlines global 90-90-90 goals to achieve epidemic control by having 90% of infected people know their status, 90% on antiretroviral therapy, and 90% virally suppressed. While some countries like Zambia have met 90-90-90 targets, new global infections remain off target for epidemic control due to declining rates of status awareness, treatment coverage, and viral suppression in recent years.
This document summarizes disparities in Philadelphia's HIV continuum of care. It identifies several priority populations that experience lower rates of HIV status awareness, retention in medical care, and viral load suppression. These include racial/ethnic minority youth, transgender persons who have sex with men, heterosexual men of color, and persons who inject drugs. The document also finds geographic disparities, with lower continuum measures in collar counties surrounding Philadelphia. It concludes by recommending several areas for action to decrease disparities, such as increasing PrEP access, HIV testing, and linkage to and retention in medical care.
This document provides an overview of viral load testing in Zambia. It defines viral load and viral load suppression. It discusses Zambia's achievement of 90-90-90 targets and the scale up of PCR labs across the country's 10 provinces. It reviews viral load testing platforms, sample types, and expected results and schedules for both adults and children, including a minimum 80% viral suppression rate expected in children by 6 months on first-line ART.
03 children's enhanced adherence couselling in zambia ssAlbert Mwango
This document provides an overview of children's enhanced adherence counselling in Zambia. It begins with definitions of viral suppression and treatment failure. It then reviews viral load testing and effective regimens in children, and how to manage suspected treatment failure. It discusses enhanced adherence counselling (EAC) and the process involved. EAC aims to identify reasons for non-adherence and improve adherence. The document also reviews second line antiretroviral regimens for children in Zambia.
This document provides an overview of the President's Emergency Plan for AIDS Relief (PEPFAR) program, including its goals, strategies, and challenges. PEPFAR aims to control the HIV/AIDS epidemic through strategies like testing and treatment (95-95-95 goals), focusing on high-risk populations and geographic hotspots, and strengthening HIV testing services. However, PEPFAR faces ongoing challenges like ensuring accurate HIV testing and achieving viral suppression targets among youth. The document discusses ongoing efforts to address weaknesses in HIV testing practices and increase testing quality through proficiency testing, monitoring, and training.
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
This document provides guidelines for treating and preventing HIV infection in Kenya in 2016. It summarizes recommendations for HIV testing and linkage to care, initial evaluation and follow up of people living with HIV, the standard package of care including antiretroviral therapy and prevention services, adherence preparation and monitoring, antiretroviral therapy for infants/children/adults, prevention of mother-to-child transmission, and the use of antiretrovirals for pre-exposure prophylaxis. The guidelines are intended to help healthcare workers in Kenya provide comprehensive HIV prevention and treatment services in line with best practices.
The document provides guidelines for healthcare providers in New York State on pre-exposure prophylaxis (PrEP) for HIV prevention. It recommends that PrEP with tenofovir/emtricitabine should be offered to individuals at high risk of acquiring HIV. PrEP has been shown to be over 90% effective in reducing HIV risk when taken daily as prescribed, but requires adherence to daily dosing and regular medical monitoring including HIV and STI testing every 3 months. The guidelines provide recommendations on candidate selection, counseling, prescribing and follow up care for individuals on PrEP.
Jacob Eden of the AIDS Law Project presented on Medicaid, Medicare, and ACA Insurance Plans at the November 2016 meeting of the Philadelphia EMA Ryan White Part A Planning Council.
This document provides an overview of the Ryan White HIV/AIDS Program and the Ryan White Planning Council (RWPC) in the Philadelphia Eligible Metropolitan Area. It describes the key parts and funding of the Ryan White legislation. The RWPC is responsible for conducting needs assessments, setting service priorities, allocating Part A funds, monitoring the administrative mechanism, and developing a comprehensive plan. It outlines the membership, committees, activities, and processes of the RWPC in carrying out these responsibilities.
The document discusses using HIV program data to evaluate gaps and disparities in linkage to care. It provides examples of how Louisiana measures linkage, retention, and viral suppression, and presents continuum of care data for the state overall and by region, race/ethnicity, and testing site. Linkage to care rates for newly diagnosed individuals are shown to be improving over time but still vary between regions and community-based organizations. The document encourages evaluating one's own agency's linkage data and identifying opportunities for the State HIV Program to provide more useful data support.
The Kenya HIV Testing Services Guidelines 2015Cheryl Johnson
The document provides guidelines for HIV Testing Services in Kenya. It outlines the background of HIV testing in Kenya since the first diagnosis over 30 years ago. It notes that testing approaches have evolved from expensive laboratory tests requiring complex procedures to more simplified point-of-care testing kits, resulting in more Kenyans knowing their status. The guidelines aim to ensure quality services are provided to all clients accessing health facilities for HIV services. It emphasizes updated guidance on HIV Testing Services in line with current knowledge and the country's 90-90-90 strategy to identify people living with HIV so they can access treatment.
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Hivlife Info
In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
This document provides information on PrEP (pre-exposure prophylaxis) for HIV. It discusses current US recommendations for PrEP, including identifying high-risk candidates such as men who have sex with men, transgender individuals, injection drug users, and heterosexual men and women. The document reviews PrEP clinical trials that found risk of HIV transmission was lowest with consistent PrEP use. It outlines guidelines for providing PrEP, including testing, prescribing Truvada, monitoring side effects, and supporting adherence. Discontinuing PrEP guidelines are also reviewed.
Jill Blumenthal, MD
Assistant Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
This document provides information on HIV/AIDS including its epidemiology, transmission, stages, diagnosis, treatment and prevention. It describes HIV/AIDS as a global public health issue and outlines prevention strategies like safe sex practices, antiretroviral treatment, prevention of mother-to-child transmission and harm reduction for intravenous drug users. Statistics on HIV prevalence in Pakistan are presented alongside the national AIDS control program and its strategies to promote awareness, testing and care.
HIV self-testing and linkage in Africa. The document summarizes a presentation on HIV self-testing research in Africa. It discusses (1) the need for HIV self-testing in Africa due to low testing rates and knowledge of HIV status, (2) completed and ongoing studies of HIV self-testing in various African countries, and (3) priorities for future research including improving accuracy, evaluating new models for linkage to care, and assessing implementation in different populations and settings.
What is epidemic control after 2020 mwango 04082021Albert Mwango
This document discusses epidemic control in the context of HIV/AIDS. It defines epidemic control as reaching a point where new HIV infections fall below deaths from all causes in infected individuals. It outlines global 90-90-90 goals to achieve epidemic control by having 90% of infected people know their status, 90% on antiretroviral therapy, and 90% virally suppressed. While some countries like Zambia have met 90-90-90 targets, new global infections remain off target for epidemic control due to declining rates of status awareness, treatment coverage, and viral suppression in recent years.
This document summarizes disparities in Philadelphia's HIV continuum of care. It identifies several priority populations that experience lower rates of HIV status awareness, retention in medical care, and viral load suppression. These include racial/ethnic minority youth, transgender persons who have sex with men, heterosexual men of color, and persons who inject drugs. The document also finds geographic disparities, with lower continuum measures in collar counties surrounding Philadelphia. It concludes by recommending several areas for action to decrease disparities, such as increasing PrEP access, HIV testing, and linkage to and retention in medical care.
This document provides an overview of viral load testing in Zambia. It defines viral load and viral load suppression. It discusses Zambia's achievement of 90-90-90 targets and the scale up of PCR labs across the country's 10 provinces. It reviews viral load testing platforms, sample types, and expected results and schedules for both adults and children, including a minimum 80% viral suppression rate expected in children by 6 months on first-line ART.
03 children's enhanced adherence couselling in zambia ssAlbert Mwango
This document provides an overview of children's enhanced adherence counselling in Zambia. It begins with definitions of viral suppression and treatment failure. It then reviews viral load testing and effective regimens in children, and how to manage suspected treatment failure. It discusses enhanced adherence counselling (EAC) and the process involved. EAC aims to identify reasons for non-adherence and improve adherence. The document also reviews second line antiretroviral regimens for children in Zambia.
This document provides an overview of the President's Emergency Plan for AIDS Relief (PEPFAR) program, including its goals, strategies, and challenges. PEPFAR aims to control the HIV/AIDS epidemic through strategies like testing and treatment (95-95-95 goals), focusing on high-risk populations and geographic hotspots, and strengthening HIV testing services. However, PEPFAR faces ongoing challenges like ensuring accurate HIV testing and achieving viral suppression targets among youth. The document discusses ongoing efforts to address weaknesses in HIV testing practices and increase testing quality through proficiency testing, monitoring, and training.
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
This document provides guidelines for treating and preventing HIV infection in Kenya in 2016. It summarizes recommendations for HIV testing and linkage to care, initial evaluation and follow up of people living with HIV, the standard package of care including antiretroviral therapy and prevention services, adherence preparation and monitoring, antiretroviral therapy for infants/children/adults, prevention of mother-to-child transmission, and the use of antiretrovirals for pre-exposure prophylaxis. The guidelines are intended to help healthcare workers in Kenya provide comprehensive HIV prevention and treatment services in line with best practices.
The document provides guidelines for healthcare providers in New York State on pre-exposure prophylaxis (PrEP) for HIV prevention. It recommends that PrEP with tenofovir/emtricitabine should be offered to individuals at high risk of acquiring HIV. PrEP has been shown to be over 90% effective in reducing HIV risk when taken daily as prescribed, but requires adherence to daily dosing and regular medical monitoring including HIV and STI testing every 3 months. The guidelines provide recommendations on candidate selection, counseling, prescribing and follow up care for individuals on PrEP.
Jacob Eden of the AIDS Law Project presented on Medicaid, Medicare, and ACA Insurance Plans at the November 2016 meeting of the Philadelphia EMA Ryan White Part A Planning Council.
This document provides an overview of the Ryan White HIV/AIDS Program and the Ryan White Planning Council (RWPC) in the Philadelphia Eligible Metropolitan Area. It describes the key parts and funding of the Ryan White legislation. The RWPC is responsible for conducting needs assessments, setting service priorities, allocating Part A funds, monitoring the administrative mechanism, and developing a comprehensive plan. It outlines the membership, committees, activities, and processes of the RWPC in carrying out these responsibilities.
Representatives from the Creative Arts Therapies program at Parkway Health and Wellness presented at the January, 2017 meeting of the Positive Committee. The presentation focused on what art therapy is and what services are provided at the organization.
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...Office of HIV Planning
At the October 2016 meeting of the Philadelphia Ryan White Part A Planning Council, Alex Shirreffs of the Philadelphia Department of Public Health discussed an ongoing project to improve the care continuum for HIV/HCV co-infected people of color.
The OHP's Nicole Johns reviewed the process of putting together the Integrated HIV Prevention and Care Plan at the August meeting of the Philadelphia Ryan White Part A Planning Council.
Akash Desai of the Philadelphia Department of Public Health (PDPH) presented on health insurance premium/cost-sharing assistance at the December 2016 meeting of the Ryan White Planning Council.
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)Office of HIV Planning
On April 27, 2016, Kathleen Brady of the Philadelphia AIDS Activities Coordinating Office (AACO) presented her annual review of the HIV Epidemic in Philadelphia and the surrounding areas.
Ricardo Colon and Sebastian Branca of the Philadelphia AIDS Activities Coordinating Office presented on Client Services and Quality Management in Philadelphia at the March 2017 meeting of the Ryan White Planning Council.
Kathleen Brady from the Philadelphia Department of Public Health presented her annual updated on the HIV Epidemic in Philadelphia at a February 2015 combined meeting of the Philadelphia Ryan White Part A Planning Council and the HIV Prevention Planning Group.
The document summarizes HIV care continuum and engagement in care data for Philadelphia. Key points:
- In 2010, 82% of those diagnosed with HIV in Philadelphia were linked to care, 54% remained in care, 49% were on antiretroviral therapy (ART), and 38% had suppressed viral loads.
- Engagement in care varies by demographic group - males, blacks, Latinos, MSM, and younger age groups have lower rates of retention, ART use, and viral suppression compared to females, whites, heterosexuals, and older adults.
- 18% of those living with HIV/AIDS in the Philadelphia area had unmet needs for primary medical care in 2012, with higher
Dr. Anne Frankel from Temple University presented the results of the most recent Youth Risk Behavior Survey (YRBS) in Philadelphia at the March 2016 meeting of the Philadelphia HIV Prevention Planning Group.
At the April 16th, 2016 meeting of the Philadelphia Ryan White Planning Council, Evelyn Torres and Sebastian Branca of the AIDS Activities Coordinating Office (AACO) presented their annual Client Services Unit (CSU) report.
El documento resume diferentes formas de conocer el origen de las cosas como la filosofía, ciencia, religión y magia. La filosofía busca el conocimiento a través de la razón, la ciencia usa métodos y pruebas experimentales, la religión reúne personas con creencias compartidas, y la magia pretende causar cambios mediante la mente o rituales. El documento también discute el desarrollo de la filosofía y ciencia a través de la historia.
La identidad venezolana ha sido influenciada por varias culturas y ha cambiado a través del tiempo. Actualmente, la cultura venezolana es una mezcla de las culturas indígena, española y africana, pero también ha sido influenciada por culturas modernas como la estadounidense. El descubrimiento del petróleo transformó a Venezuela de una economía agrícola a una economía basada en los hidrocarburos y generó cambios sociales como el surgimiento de una nueva clase obrera y la migración del campo a la
La identidad venezolana se ha visto influenciada por varias culturas y ha cambiado a lo largo del tiempo. La explotación del petróleo generó cambios sociales como el surgimiento de una nueva clase obrera y la migración del campo a la ciudad. Actualmente, la cultura venezolana está mezclada con influencias de otros países debido a la transculturización e inmigración. Además, la sociedad venezolana se ha vuelto más diversa y dividida políticamente.
Este documento presenta la línea de tiempo personal de Gabriela Linares. Resume los hitos más importantes de su vida, incluyendo su educación desde el preescolar hasta la universidad donde actualmente estudia psicología y medicina. También describe brevemente su niñez, adolescencia y vida espiritual. Por último, incluye sus aspiraciones y metas de futuro como lograr el éxito a través de Dios, convertirse en una excelente profesional y tener una familia luego de completar sus estudios universitarios.
Este documento presenta la línea de tiempo personal de Gabriela Linares. Resume los hitos más importantes de su vida desde su nacimiento hasta el presente, incluyendo su educación prescolar, primaria y bachillerato. También describe su vida espiritual, niñez y adolescencia. Actualmente estudia Psicología y Medicina en la universidad, y aspira a tener éxito como profesional y formar una familia en el futuro mientras sigue el llamado de Dios como profeta.
Social work in Uganda face very many challenges that range from Political , economic and social . Many scholars have tried to come up with a developmental approach to social work and they have kept on asking whether it is applicable to the Ugandan context. This writing reflects my view on developmental social work .
Dr. Kathleen Brady (AACO)'s annual epidemiological update. This presentation was given to the Philadelphia EMA Ryan White Planning Council on Thursday, February 20, 2014.
The document summarizes HIV engagement in care data for Philadelphia and nationally. It finds that in Philadelphia in 2009, 82% of people living with HIV were aware of their infection, 62% were linked to care, 52% were retained in care, 46% were prescribed antiretroviral therapy (ART), and 30% had viral suppression. Nationally, the rates were slightly higher. The epidemic in Philadelphia primarily affects minorities and transmission is mostly through men who have sex with men and heterosexual contact. While new AIDS cases have declined 25%, growing numbers are living with HIV. Around 20-30% have unmet needs and are not engaged in regular HIV care.
Dr. Kathleen Brady of Philadelphia's AIDS Activities Coordinating Office (AACO) gave this presentation at the January 9, 2013 Comprehensive Planning Committee meeting.
The UC San Diego AntiViral Research Center sponsors weekly presentations on infectious diseases research and clinical practices. A presentation on whether widespread HIV treatment can end transmission discussed recent trends showing HIV declining among adolescents and young adults in the US. The presentation reviewed research showing that early HIV treatment dramatically reduces heterosexual transmission but some transmission may still occur through anal sex among men who have sex with men on antiretroviral therapy. Future interventions could focus on optimizing HIV treatment, comparing antiretroviral regimens, and suppressing coinfections like CMV to further reduce HIV transmission.
Where are we on HIV testing services - the achievements and the gapsCheryl Johnson
This document discusses achievements and gaps in HIV testing services globally. It finds that approximately 17 million people with HIV still do not know their status, and linkage to treatment after testing is suboptimal. While over 150 million people received HIV testing in 2014, nearly half of all people with HIV remain undiagnosed globally, with lower testing rates among men, adolescents, and key populations. The document calls for new approaches to testing like self-testing and lay providers, as well as improving quality, coverage, and focus on missing populations and areas with ongoing high risk.
Getting to scale: How we can achieve the reach required of prevention service...HopkinsCFAR
This document discusses disparities in HIV/STI rates among Black and White MSM in Atlanta from 2009-2014. The study found significantly higher rates of new HIV infections, prevalent HIV infections, and STIs among Black MSM compared to White MSM. Factors contributing to the disparities included higher community-level HIV prevalence among Black MSM networks, increased likelihood of Black MSM encountering an HIV-positive partner, geographic clustering of Black MSM in high-poverty/high-stigma neighborhoods, and higher rates of condom failures or incomplete use among Black MSM. The document advocates for scaling up multiple prevention interventions like PrEP to achieve sufficient coverage levels to meaningfully reduce new HIV transmissions.
This document summarizes a presentation on hepatitis C virus (HCV) epidemiology and screening recommendations. It discusses global and local HCV prevalence, the health impacts and economic costs of HCV infection, and the potential for HCV elimination with new direct-acting antiviral treatments. It also reviews evolving HCV screening guidelines and epidemiologic trends in the US, including increasing infections associated with opioid epidemics. Risk factors for HCV transmission are identified based on a study of HCV-positive blood donors.
Estimation of HIV incidence in Malawi from cross-sectional population-based s...Humphrey Misiri
This document summarizes a study that estimated HIV incidence rates in Malawi using cross-sectional population data from 2004. The researchers formulated a recurrence relation to model population prevalence over time based on a piecewise-constant force of HIV infection that adjusts for natural and HIV-induced mortality. They estimated parameters by maximum likelihood and assessed model fit. Estimated HIV incidence per 100,000 person-years was 610 for men aged 15-24, 2700 for men 25-34, and 1320 for men 35-49. For women it was 2030 for 15-24, 1710 for 25-34, and 1730 for 35-49. The method provides a simple way to estimate incidence from cross-sectional prevalence data
Estimation of HIV incidence in Malawi from cross-sectional population-based s...Humphrey Misiri
This document summarizes a study that estimated HIV incidence rates in Malawi using cross-sectional HIV prevalence data from the 2004 Malawi Demographic and Health Survey. The researchers developed a recurrence relation to model population prevalence over age groups as a function of age-specific force of infection (FOI) and mortality rates. They estimated parameters by maximum likelihood and assessed model fit. Estimated HIV incidence per 100,000 person-years was highest for females ages 15-24 (2030) and males ages 25-34 (2700), and lowest for males ages 15-24 (610). The method provides a simple way to simultaneously estimate incidence and prevalence from single-time-point cross-sectional data.
This document provides an overview of an HIV update presentation given by Dr. Ellen Tedaldi. It discusses the epidemiology of HIV in Philadelphia, noting higher rates than national averages and most new infections occurring in heterosexuals aged 25-45. It covers screening and diagnosis guidelines, evaluation of HIV+ patients, treatment updates including the benefits of early antiretroviral therapy initiation, and ophthalmology considerations for patients with low CD4 counts. Key aspects of monitoring and management of HIV patients are summarized, including recommended initial antiretroviral regimens and the importance of adherence for long-term treatment success.
This document introduces a new Health System Navigator program in Philadelphia aimed at improving linkage to and retention in HIV care. It notes challenges with late diagnosis, linkage to care, and patient retention. Health System Navigators will help HIV-positive patients navigate health systems and address barriers to staying engaged in care. Navigators will work with newly diagnosed patients, those lost to care, and those loosely engaged to improve testing, linkage, and retention through individual support and system navigation. The program is a collaboration between ActionAIDS and Philadelphia health centers.
This document summarizes key information about HIV in the United States:
- Over 1.1 million people are living with HIV in the US, with about 56,000 new infections each year. Rates are highest among men who have sex with men, African Americans, Latinos, and intravenous drug users.
- Effective prevention strategies include promoting abstinence, fewer partners, condom use, not sharing needles, antiretroviral treatment, male circumcision, and pre-exposure prophylaxis. Widespread testing is also an important prevention approach.
- Combining multiple prevention approaches and targeting high-risk groups can maximize the impact of HIV prevention and reduce transmission rates in the US.
The document discusses using HIV program data to evaluate gaps and disparities in linkage to care. It provides examples of how Louisiana measures linkage, retention, and viral suppression, and presents HIV continuum of care data for the state overall and by region, race/ethnicity, and testing site. Linkage to care rates for newly diagnosed individuals are shown to be improving over time but still lag the national goal of 85% linked within 90 days. Community-based organizations see variation in their linkage rates that could be improved. The presentation raises questions about how agencies evaluate their own linkage efforts and ways state assistance could strengthen local data collection and use.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
This document summarizes national HIV prevention and care outcomes in the United States. Key metrics monitored include linkage to care after HIV diagnosis, retention in care, and viral suppression. Data on these indicators are collected through the National HIV Surveillance System and used to measure progress towards national goals. The document provides data on these indicators stratified by factors such as age, gender, race/ethnicity, and transmission category. It also discusses calculation methods and presents graphs illustrating trends in various indicators over time and across populations.
India has seen a 57% reduction in its HIV count between 2001-2011, while Bangladesh and Sri Lanka saw increases of 25%. As of 2011, an estimated 2.1 million people in India were living with HIV. India's epidemic is heterogeneous and concentrated in certain states and sub-populations. Successful prevention efforts have led international figures to praise India's HIV/AIDS prevention model. However, more work remains as even a small increase in prevalence could mean over half a million new infections. The continuum of HIV care involves testing and counseling, treatment of opportunistic infections, anti-retroviral therapy initiation and monitoring, management of co-infections, and adherence support. WHO guidelines recommend treatment for all HIV-positive individuals
Similar to Annual Epidemiological Presentation, 2017 - Kathleen Brady, PDPH (20)
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...Office of HIV Planning
Mari Ross-Russell (Office of HIV Planning) and Matthew McClain (Public Health Policy & Planning Consultant) presented these slides to the PrEP Workgroup of the Philadelphia EMA HIV Integrated Planning Council on January 16, 2019.
Dr. William R. Short presented this review of PrEP research from the Conference on Retroviruses and Opportunistic Infections to the PrEP Workgroup of the HIPC's Prevention Committee in April 2018.
Sebastian Branca of the AIDS Activities Coordinating Office provided this overview of AACO's quality management program to the HIV Integrated Planning Council on May 10, 2018. This presentation includes discussion of secret shoppers, quality improvement plans, and quality management initiatives.
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...Office of HIV Planning
Alex Shirreffs of the Philadelphia Department of Public Health provided this overview of the Philadelphia area's plan to end HIV and Hepatitis C coinfections to the HIV Integrated Planning Council on May 10, 2018.
The document outlines information about the Client Services Unit (CSU) of the AIDS Activities Coordinating Office (AACO) in Philadelphia. It discusses the CSU's mission to help and advocate for people living with HIV/AIDS. It provides data on the 1976 client intakes completed in 2017, including demographics and most common needs. It also describes the transition of AACO's Housing Services Program to the City's Office of Homeless Services and details the consumer feedback process for AACO-funded services.
This presentation was provided to the Philadelphia EMA HIV Integrated Planning Council by Briana Morgan of the Office of HIV Planning. It includes data related to population-level data, race/ethnicity, STIs, risk behaviors, HIV, and more.
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...Office of HIV Planning
Silvana Mazzella of Prevention Point Philadelphia gave this presentation on medication assisted treatment to the Philadelphia EMA HIV Integrated Planning Council on March 8, 2018.
Dr. Kathleen Brady of the AIDS Activities Coordinating Office discussed three cycles of the National HIV Behavioral Surveillance in Philadelphia, including cycles with men who have sex with men (MSM), high-risk heterosexuals, and injection drug users. This presentation took place at the Philadelphia EMA HIV Integrated Planning Council meeting on Thursday, January 11, 2018.
Caitlin Conyngham and Erika Aaron of the AIDS Activities Coordinating Office began the initial meeting of the PrEP Working Group with this presentation on November 15, 2017.
Antonio Boone of the Office of HIV Planning reviewed major points from the Mayor's Task Force to Combat the Opioid Epidemic in Philadelphia at the June 12, 2017 Positive Committee meeting.
Marcy Witherspoon, MSW, LSW of the Health Federation of Philadelphia discussed trauma-informed care with the Philadelphia EMA HIV Integrated Planning Council on November 9, 2018.
OHP's Antonio Boone gave this presentation on different prevention continuum examples at the July meeting of the Prevention Committee of the Philadelphia EMA HIV Integrated Planning Council.
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...Office of HIV Planning
Caitlin Conyngham, Prevention Coordinator at the AIDS Activities Coordinating Office at the Philadelphia Department of Public Health, gave an overview of the new HIV prevention notice of funding opportunity to the HIPC's Prevention Committee on 07-26-2017.
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...Office of HIV Planning
The document summarizes a report by the Mayor's Task Force to Combat the Opioid Epidemic in Philadelphia. It finds that prescription opioid sales doubled from 2000-2012, fueling high rates of opioid use, overdoses, and deaths. The Task Force made recommendations in areas of prevention, treatment, overdose prevention, and criminal justice system involvement. Key recommendations included expanding access to medication-assisted treatment, naloxone distribution, and treatment services in prisons. The report calls for increased monitoring and evaluation to assess progress combating the epidemic.
Planning Council Co-Chair and Prevention Committee member Jen Chapman presented on integrated planning and concurrence at the May 2017 meeting of the HIV Integrated Planning Council.
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...Office of HIV Planning
At the April meeting of the Comprehensive Planning and Needs Assessment Committees, Jessica Brown of AACO presented on Ryan White service categories. She also reviewed changes enacted by PCN 16-02.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
1. HIV in Philadelphia
Kathleen A. Brady, MD
Medical Director/Medical Epidemiologist
AIDS Activities Coordinating Office
Philadelphia Department of Public Health
Office of HIV Planning Epi Update
February 9, 2017
3. HIV Care Continuum
Adapted from
Eldred et al AIDS Patient Care STDs 2007;21(Suppl1):S1-S2
Cheever LW Clin Infect Dis 2007;44:1500-2
Not in HIV Care Engaged in HIV Care
Unaware of
HIV infection
Aware of
HIV infection
(not in care)
Receiving some
medical care but
not HIV care
Entered HIV
care but lost to
follow-up
Cyclical or
intermittent user
of HIV care
Fully engaged
in HIV care
4. CDC HIV Continuum Measures
Aligns with NHAS 2020 indicator definitions
Represents the best available data for measuring progress
Uses National HIV Surveillance System (NHSS) data which meet the NHAS
indicator data source criteria
– Timely and routine
– Can stratify by demographic characteristics
– Prioritized data sources that are available at the state level to allow
states ability to monitor progress toward Strategy goals in their
jurisdictions
Uses different denominators for each measure
5. Calculation of Indicators
Prevalence of diagnosed HIV – United States
– Numerator: Persons aged ≥13 years living with diagnosed HIV
infection year-end 2013
– Denominator: Persons aged ≥13 years living with diagnosed or
undiagnosed HIV infection year-end 2013 (derived using back-
calculation)
The following indicators only use data from areas with complete
reporting of CD4 and viral load test results to CDC (32 states and the
District of Columbia):
– Linkage to care (within 1 month)
– Retention in care
– Viral suppression
6. Diagnosed Infection among Persons Aged ≥13 Years Living with Diagnosed or
Undiagnosed HIV Infection, by Sex, 2013—United States
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Estimates were derived by using back-
calculation on HIV data for persons aged ≥13 years at diagnosis in the 50 states and the District of Columbia.
7. Diagnosed Infection among Persons Aged ≥13 Years Living with Diagnosed or
Undiagnosed HIV Infection, by Age, 2013—United States
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Estimates were derived by using back-
calculation on HIV data for persons aged ≥13 years at diagnosis in the 50 states and the District of Columbia.
8. Unaware Estimates by Select Demographic
Groups, Philadelphia, 2014
Demographic Group % Unaware (95% CI)
Sex
Female 4.7% (0.0 %-9.8%)
Male 7.7% (3.8%-11.2%)
Race/Ethnicity
Black 8.5% (4.3%-12.4%)
Hispanic 4.4% (0%-11.4%)
White/Other 5.2% (0.1%-12.2%)
Mode of Transmission
Heterosexual 9.5% (9.0%-19.1%)
IDU (including MSM/IDU) 0.0% (0.0%-2.2%)
MSM 9.2% (4.0%-15.0%)
Total 7.0% (4.0% – 10.4%)
Source: PDPH, AIDS Activities Coordinating Office, 2016
9. EMA Concurrent HIV/AIDS
29.7% 29.1%
26.1% 24.9% 23.5%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
2011 2012 2013 2014 2015
Philly PA Counties NJ Counties EMA
10. Concurrent HIV/AIDS, 2014 - 2015
Year
2014 2015
Non-concurrent Concurrent HIV/AIDS Non-concurrent Concurrent HIV/AIDS
N Col % N Col % N Col % N Col %
Total 444 78.0% 125 22.0% 433 80.5% 105 19.5%
Sex
Female 89 74.2% 31 25.8% 95 80.5% 23 19.5%
Male 35 79.1% 94 20.9% 338 80.5% 82 19.5%
Race/
Ethnicity
Black 294 76.2% 92 23.8% 312 80.0% 78 20.0%
Hispanic 63 88.7% 8 11.3% 66 86.8% 10 13.2%
White 70 80.5% 17 19.5% 46 82.1% 10 17.9%
Asian 10 76.9% * 23.1% * 45.5% 6 54.5%
Multi-race * 50.0% * 50.0% * 50.0% * 50.0%
Other/Unk * 75.0% * 25.0% * 100.0% 0 0.0%
Source: PDPH, AIDS Activities Coordinating Office, 2016
12. Calculation of Indicators
Linkage to care
– Numerator: Persons aged ≥13 years who were diagnosed during 2014
and who had ≥1 viral load (VL) or CD4 test within 1 month of HIV
diagnosis
– Denominator: Persons aged ≥13 years who were diagnosed during 2014
(32 states and the District of Columbia)
13. Linkage to HIV Medical Care within 1 Month after HIV Diagnosis during 2014,
among Persons Aged ≥13 Years, by Sex—32 States and the District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Linkage to HIV medical care was defined as
having a CD4 or VL test ≤1 month after HIV diagnosis.
14. Linkage to HIV Medical Care within 1 Month after HIV Diagnosis during 2014,
among Persons Aged ≥13 Years, by Transmission Category—32 States and the
District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Linkage to HIV medical care was defined as
having a CD4 or VL test ≤1 month after HIV diagnosis. Heterosexual contact is with a person known to have, or be at high risk for, HIV infection.
MSM, male-to-male sexual contact; IDU, injection drug use
15. 2011 2012 2013 2014 2015
Linkage 30 Days 75 75 72 77 81
Linkage 90 Days 81 81 78 82 91
0
20
40
60
80
100
Percentage(%) Care Continuum Measures
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
Philadelphia Linkage to Care Indicators, 2011-2015
16. Calculation of Indicators
Retention in care
– Numerator: Persons aged ≥13 years with ≥2 tests (CD4 or VL) at least ≥3
months apart in 2013
– Denominator: Persons aged ≥13 years who were diagnosed by year-end
2012 and alive at year-end 2013 (32 states and the District of Columbia)
Viral suppression
– Numerator: Persons aged ≥13 years with <200 copies/mL on their most
recent VL test in 2013
– Denominator: Persons aged ≥13 years who were diagnosed by year-end
2012 and alive at year-end 2013 (32 states and the District of Columbia)
17. Retention in HIV Medical Care and Viral Suppression among Persons Aged ≥13
Years Living with Diagnosed HIV Infection, by Sex, 2013—32 States and the
District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Retained in medical care was defined as ≥2
tests (CD4 or VL) ≥3 months apart in 2013. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2013.
18. Retention in HIV Medical Care and Viral Suppression among Persons Aged ≥13
Years Living with Diagnosed HIV Infection, by Transmission Category, 2013—32
States and the District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Retained in medical care was defined as ≥2
tests (CD4 or VL) ≥3 months apart in 2013. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2013. Heterosexual
contact is with a person known to have, or be at high risk for, HIV infection. MSM, male-to-male sexual contact; IDU, injection drug use
19. 2011 2012 2013 2014 2015
Retention* 47 51 52 52 53
Suppression* 44 49 50 53 56
0
20
40
60
80
100
Percentage(%) Care Continuum Measures
*Significant increase between 2011 and 2015 (p<0.0001)
Philadelphia Diagnosis-Based HIV Care Continuum, 2011-2015
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
20. 87%
75%
49% 48%
0%
20%
40%
60%
80%
100%
HIV-Diagnosed Linked to Care
(2015 New Cases)
In HIV Care
during 2015
Suppressed VL
(<200copies/mL)
US Prevalence-Based HIV Care Continuum, 2013
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
21. 93% 91%
49% 52%
0%
20%
40%
60%
80%
100%
HIV-Diagnosed Linked to Care
(2015 New Cases)
In HIV Care
during 2015
Suppressed VL
(<200copies/mL)
19,280 488/538
10,173 10,758
Philadelphia Prevalence-Based HIV Care
Continuum, 2015
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
22. US* Philadelphia**
Number
87 Diagnosed
75 Are linked to HIV care
49 Stay in HIV care
48
Have a very low amount
of virus in their body
Number
93 Diagnosed
91 Are linked to HIV care
49 Stay in HIV care
52
Have a very low amount
of virus in their body
For every 100 people living with HIV:
*2013 Data **2015 Data
24. Newly Diagnosed HIV Cases, Deaths, and Living HIV Cases by Year
Philadelphia, 2008-2015
928 897
739 694 737
634 569 538523 513 550 473 434 497
349 312
18640
19237
19525
19157
19832
19564 19494 19280
15000
16000
17000
18000
19000
20000
0
500
1000
1500
2000
2008 2009 2010 2011 2012 2013 2014 2015
Newly Diagnosed Deaths Living HIV Cases
Source: PDPH, AIDS Activities Coordinating Office, 2016
25. Rates of Adults and Adolescents Living with Diagnosed HIV Infection, by Area of
Residence, Year-end 2014 — United States and 6 Dependent Areas
N = 970,319 Total Rate: 360.0
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data are based on address of residence as of
December 31, 2014 (i.e., most recent known address).
26.
27. Persons Living with HIV/AIDS by Census Tract,
Philadelphia, 2015
Source: PDPH, AIDS Activities Coordinating Office, 2016
28. Comparison of HIV Prevalence in the
US and Philadelphia
Philadelphia EMA
• 26,807 PLWH as of 12/2015
– 482.6/100,000 population
– 1,263.4/100,000 in Philadelphia
• 57.9% black, 15.0% Latino, 22.8% white
• 70.9% male
• 48.8% current age >50 and 24.6% 40-49
• MSM – 35.5%, IDU – 21.3%,
Heterosexual – 34.8%
• Majority of cases among blacks,
regardless of risk
United States
• 955,081 as of 12/2014
– Rate 299.5/100,000 population
• 42.4% black, 20.8% Latino, 31.4%
white
• 75.6% male
• 44.9% current age >50 and 27.6%
40-49
• MSM – 53.3%, IDU – 13.7%,
Heterosexual – 25.8%
• Highest rates of HIV in the
Northeast US
Sources: PDPH, AIDS Activities Coordinating Office, 2016
https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf
29. Proportion of Philadelphia Residents Diagnosed and Living with HIV by
Race/Ethnicity and Sex, 2015
2.9%
2.3%
1.1% 1.1% 0.9%
0.2%
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
Black Males Hispanic
Males
Black
Females
White Males Hispanic
Females
White
Females
Overall Prevalence 1.3%
Epidemic Level 1.0%
Source: PDPH, AIDS Activities Coordinating Office, 2016
30. Proportion of Philadelphia EMA Residents Diagnosed
and Living with HIV by Race/Ethnicity and Sex, 2015
2.9%
2.3%
1.1% 1.1% 0.9%
0.2%
1.0%
0.6% 0.5% 0.1% 0.4%
0.0%
1.0% 0.8% 0.5% 0.2% 0.4%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
Black Males Hispanic
Males
Black
Females
White Males Hispanic
Females
White
Females
Philly PA counties NJ Counties
33. Newly Diagnosed HIV Cases, Deaths, and Living HIV Cases by Year
Philadelphia, 2008-2015
928 897
739 694 737
634 569 538523 513 550 473 434 497
349 312
18640
19237
19525
19157
19832
19564 19494 19280
15000
16000
17000
18000
19000
20000
0
500
1000
1500
2000
2008 2009 2010 2011 2012 2013 2014 2015
Newly Diagnosed Deaths Living HIV Cases
Source: PDPH, AIDS Activities Coordinating Office, 2016
34. Rates of Diagnoses of HIV Infection among Adults and Adolescents, by Area of
Residence, 2015 — United States and 6 Dependent Areas
N = 39,920 Total Rate: 14.7
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data for the year 2015 are preliminary and based on 6
months reporting delay.
35. Persons Diagnosed with HIV (regardless of AIDS status)
by Census Tract, Philadelphia, 2015
Source: PDPH, AIDS Activities Coordinating Office, 2016
36. Newly Diagnosed HIV United States,
2014
• 44,073 estimated cases
• 80.7% male at birth
• 43.7% black, 24.3%
Hispanic, 26.9% white
• 22.0% among 13-24
year olds
66.5%
6.1%
24.1%
2.7%0.4%0.2%
Mode of Transmission
MSM IDU HET
MSM/IDU Pediatric NIR
Source: http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-
surveillance-report-us.pdf
37. Newly Diagnosed HIV Philadelphia,
2015
• 538 Newly Diagnosed
cases
• 78.0% male at birth
• 72.4% black, 14.1%
Hispanic, 10.4% white
• 25.0% among 13-24
year olds
56.5%
5.5%
35.1%
0.4%0.5% 2.0%
Mode of Transmission
MSM IDU HET
MSM/IDU Pediatric NIR
Source: PDPH, AIDS Activities Coordinating Office, 2016
38. Newly Diagnosed HIV Disease by Age at Diagnosis
(regardless of HIV status)
41 33
222
269
232
197 193
129
111
97 88
127 133
113 121
92
34
33
44
129
120147151
154
164
114
0
50
100
150
200
250
300
2010 2011 2012 2013 2014 2015
Year
NumberofCases
13-19 20-29 30-39 40-49 50+
39. Newly Diagnosed HIV Disease by Race/Ethnicity
(regardless of HIV status)
105 93
68
87
56
486
508
474
386 390
91
114
69 71 76
0
100
200
300
400
500
600
2010 2011 2012 2013 2014 2015
Year
NumberofCases
White AfrAm Hispanic
40. Newly Diagnosed HIV Disease by Sex at
Birth (regardless of AIDS status)
0
100
200
300
400
500
600
2010 2011 2012 2013 2014 2015
Year
NumberofCases
HIV Female HIV Male
41. 41
Newly Diagnosed HIV Disease by Mode of
Transmission (regardless of AIDS status)
286
300
70
83
40 40 30
250
8 6 11
304
291
322
189
225
313313
30
9
0
50
100
150
200
250
300
350
2010 2011 2012 2013 2014 2015
Year
NumberofCases
MSM IDU HetSx NIR
42. Rates of Newly Diagnosed HIV/AIDS per 100,000
population, Philadelphia 2011-2015
43. Newly Diagnosed HIV (Non-AIDS) for
2015, Philadelphia EMA
EMA
Total
N=596
EMA
%
Phila
N=433
%
PA
N=85
%
NJ
N=78
%
Race/Ethnicity
White, non-Hispanic 98 16.4 10.6 42.4 20.5
Black, non-Hispanic 399 66.9 72.1 48.2 59.0
Hispanic 87 14.6 15.2 8.2 17.9
Asian/Pacific Islander 7 1.2 1.4 1.2 0.0
American Indian/Alaskan
Native
<6 0.2 0.2 0.0 0.0
Multi-Race <6 0.3 0.5 0.0 0.0
Gender
Male 449 70.2 75.5 72.9 76.9
44. Newly Diagnosed HIV (Non-AIDS) for
2015, Philadelphia EMA
EMA
Total
N=596
EMA
%
Phila
N=433
%
PA
N=85
%
NJ
N=78
%
Age
<13 years <6 0.3 0.8 0.0 0.0
13 - 19 years 38 6.4 7.6 2.4 3.8
20-24 years 128 21.5 22.2 16.5 23.1
25-29 years 121 20.3 18.7 18.8 30.8
30-39 years 127 21.3 23.3 15.3 16.7
40-49 years 79 13.3 13.2 17.6 9.0
50+ years 101 16.9 14.5 29.4 16.7
45. Newly Diagnosed HIV (Non-AIDS) for
2015, Philadelphia EMA
EMA
Total
N=596
EMA
%
Phila
N=433
%
PA
N=85
%
NJ
N=78
%
Mode of Transmission
Men who have sex with men
(MSM)
326 54.7 58.4 44.7 4.9
Injection drug users (IDU) 39 6.5 6.2 5.9 9.0
MSM/IDU <6 0.3 0.2 1.2 0.0
Heterosexuals 207 34.7 32.8 41.2 38.5
Other/hemophilia/blood
transfusion
0 0.0 0.0 0.0 0.0
Perinatal exposures <6 0.7 0.5 0.0 0.0
Risk not reported or identified 20 5.0 1.8 7.1 7.7
47. 2014 Local Estimate of
HIV Incidence
• Local estimate of 299 new HIV infections in
2014 in adults and adolescents (95% CI, 205-
393)
• Significant reduction since 2012
– 618 estimated HIV infections (95% CI, 419-817)
Source: PDPH, AIDS Activities Coordinating Office, 2016
48. HIV Incidence Trends by Demographic
Groups
0
200
400
600
800
1000
1200
2006 2007 2008 2009 2011 2012 2013 2014
Total Age 13-24 Male Black MSM
Source: PDPH, AIDS Activities Coordinating Office, 2016
49. Estimated Incidence Rates - 2014
Population Population in 2010
(13 +)
ESTIMATED
Incidence
Estimate,
2014
Estimated
Case Rate per
100,000
95% CI
lower
bound
95% CI
upper
bound
MSM 233,550 196 584.2 363.6 801.8
IDU 26,400 33 125.0 22.7 223.5
HET 269,231* 70 26.0 12.3 39.7
*Includes persons >13 living in poverty
Data Source: PDPH/AACO HIV Incidence Surveillance Program, 2016
51. Annual Retention, Annual Viral Suppression, and Durable
Viral Suppression by Ryan White Care, 2010-2014
52.8
63.3
46
19.2
27.8
20.4
0
20
40
60
80
100
Annual Retention
in Care*
Annual Viral
Suppression*
Durable Viral
Suppression*
Percent(%)
Ryan White
Non-Ryan White
*p<0.0001
Source: Philadelphia Department of Public Health, 2016
52. Philadelphia HIV Care Continuum 2015
0%
20%
40%
60%
80%
100%
Diagnosed Linked In Care Retained in
Care
Prescribed
ART
Virally
Suppressed
ALL PLWHA MSM of Color AA Men
Youth 13-24 AA Women Transgender
Source: PDPH, AIDS Activities Coordinating Office, 2016
53. Philadelphia HIV Care Continuum 2015
0%
20%
40%
60%
80%
100%
ALL PLWHA MSM of
Color
AA Men Youth 13-24 AA Women Transgender
Diagnosed Linked In Care
Retained in Care Prescribed ART Virally Suppressed
Source: PDPH, AIDS Activities Coordinating Office, 2016